APOPTOSIS AND CELL CYCLE
Abstract
Apoptosis, a form of programmed cell death, is used to eliminate individual cells surrounded by normal cell population. It is a controlled way of cell death in which the cell actively participates by conducting precise, gene-regulated program of self-destruction, that is. cell "suicide." Active synthesis of macromolecules is necessary during this process. Death of individual cells is necessary to maintain a balance in living systems, so the process of apoptosis is continuously present in the body, which allows normal development, tissue homeostasis, and many other physiological processes. The molecular mechanisms that regulate apoptosis are functionally linked to other cellular mechanisms, such as control of the cell cycle, cell proliferation and differentiation, genomic stability and cellular metabolism. Damage to the DNA molecule, caused both spontaneously and under the influence of various chemical and physical agents, lead to the cell cycle arrest and activation of mechanisms that repair the damage. Depending on the type and extent of damage, the cell either continues progression through the cell cycle, or activates the mechanisms that lead to apoptosis. Disturbances in the regulation of apoptosis and cell cycle present the molecular and biological basis of many diseases. Because of the importance of these processes during the development and progression of tumors, their use as biological markers is one of the main strategies in the formation of therapeutic approaches for the treatment of cancer.
References
Trump BF, Berezesky IK, Chang SH, Phelps.PC. The pathways of cell death: oncosis, apoptosis and necrosis. Toxicol Pathology 1997; 25(1): 82-8.
Saikumar P, Dong Z, Mikhailov V, Denton M, Wein-berg JM, Venkatachalam MA. Apoptosis: definition, mechanism and relevance to disease. Am J Med 1999;107:489-506.
Ristić-Fira A, Petrović I, Todorović D, et al. Ina-ctivation of HTB63 human melanoma cells by irradiation with protons and gamma rays. Oncology Rep2004;12:1323-8.
Paidassi H, Tecnet-Delorme P, Arlaud GJ, Frachet P. How phagocytes track down and respond to apoptotic cells. Crit Rev Immunol 2009; 29: 111-30.
Willis SN, Adams JM, Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17(6): 617-25.
Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med 2010;9(45):145-52.
Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-mediated apoptosis and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
Nieminen AI, Partanen JI, Klefstorm J. c-Myc blaying a trail of death. Cell Cycle2007; 6(20): 2464-72.
Fisher D, Krasinska L, Coudreuse D, Novak B. Phosphorylation network dynamics in the control of cell cycle transitions. Journal of Cell Science 2012; 125: 4703-11.
Hindley C, Philpott A. The cell cycle and pluripotency. Biochem J 2013; 451: 135-43.
PietenpolJA., StewartZA. Cellcyclecheckpointsigna-ling: cellcyclearrestversusapoptosis. Toxicology 2002; 181-182: 475-81.
Langerak P, Russell P. Regulatory networks integrating cell cycle control with DNA damage checkpoints and double-strand break repair. Phil Trans R Soc B 2011; 366: 3562-71.
Porter LA, Donoghue DJ. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog.Cell Cycle Res 2003; 5:335-47.
Leena Sankari S, Masthan KMK, Aravindha Babu N, Bhattacharjee T, Elumalai M. Apoptosis in cancer - an update. Asian Pacific Journal of Cancer Prevention 2012; 13: 4873-78.
Ohnishi T. The role of the p53 molecule in cancer therapies with radiation and/or hyperthermia. J Cancer Res Ther 2005;1(3):147-50.
Parker LP, Wolf JK, Price JE. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines. Ann Clin Lab Sci 2000;30:395–405.
Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008;9:231-41.
Finnberg N, El-Deirz WS. TRAIL death receptors as tumor supressors and drug targets.Cell Cycle 2008; 7(11): 1525-28.
Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis2004; 9: 691-704.
WeiY, FanT, YuM. Inhibitorofapoptosisproteinsan-dapoptosis. ActaBiochimBiophysSin 2008; 40(4): 278-88.
Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 2010;9(6):417-22.
Nemunaitis J, Nemunaitis J.Head and neck cancer: response to p53-based therapeutics. Head Neck2011; 33(1):131-4.
Rosato RR, Almenara JA, Kolla SS, et al.http://www.ncbi.nlm.nih.gov/ pubmed?term=%22Dent%20P%22%5BAuthor%5D Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileucemic interaction. Molecular Cancer Therapy 2007; 6: 692-702.
Elrod H, Su SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2008; 7(2): 163-73.
Kuijlen JM, Bremer E, Mooij JJ, den Dunnen WF, Helfrich W. Review: on TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol 2010; 36(3): 168-82.
Zhang C, Wu R, Zhu H, et al. Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo. Cancer Lett 2011; 302(1): 11-9.
Philchenkov A, Zavelevich M, Kroczak TJ, Los M.Caspases and cancer: mechanisms of inactivation and new treatment modalitiesExp Oncol2004;26(2):82-97.
Veselý J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analoguesEur J Biochem 1994;224(2):771-86.
Pumfery A, de la Fuente C, Berro R, Nekhai S, Kashanchi F, Chao SH. Potential use of pharma-cological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr Pharm Des 2006;12(16):1949-61.
Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.Leukemia 2001;15(1):1-9.